Illumina Inc (ILMN)

351.65
+4.37(+1.26%)
After Hours
351.65
0.00(0.00%)
- Real-time Data
  • Volume:
    1,095,200
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    342.07 - 353.60

ILMN Overview

Prev. Close
347.28
Day's Range
342.07-353.6
Revenue
4.28B
Open
345.92
52 wk Range
335.68-555.77
EPS
6.07
Volume
1,095,200
Market Cap
54.96B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
853,045
P/E Ratio
57.96
Beta
0.9
1-Year Change
0.28%
Shares Outstanding
156,300,000
Next Earnings Date
Feb 01, 2022
What is your sentiment on Illumina Inc?
or
Market is currently closed. Voting is open during market hours.

Illumina Inc Company Profile

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellNeutralStrong SellNeutral
Technical IndicatorsSellStrong BuyStrong BuyStrong SellStrong Sell
SummaryNeutralNeutralBuyStrong SellSell
  • https://www.bloomberg.com/news/articles/2021-11-29/omicron-tests-biden-s-1-7-billion-plan-to-better-track-variants
    0
    • should i hold?
      0
      • why Illumina corrected after this great earnings?
        0
        • I think for the next EU fine on Grail acquisition
          0
      • IS IT AWEFUL?
        1
        • t
          1
          • should rise on earnings
            1
            • yeah "should"
              0
          • If the trial of Grail's Galeri test with the NHS is a success this stock is going to fly into the stratosphere. Imagine getting an early cancer test with your run of the mill blood draw at the doctors office. Billions in sales per month, millions of lives saved and reduced overall medical expenses. Watching this guy closely.
            2
            • Lol why keep falling tf
              0
              • when the share price go to 550 and above? i am waiting to sell my stock.
                0
                • ah too expensive bubble
                  10
                  • SNDL very cheap drugs company 0.51 USD that will reach 2 or 3 USD.. Other Drugs like Aurora reach 6USD.. Buying 5K shares and hold it is very good idea.. Good luck guys..
                    1
                    • Good call its right at $2.09 today.
                      0
                  • Wow, goes up everyday kind of stock, nice.
                    0
                    • Looking at all the downgrade today, it looks like nobody liked the fact Ilmn bought back something they  span off not long ago for 20% of their market cap, pretty amazingly they still went ahead and finish the deal. This Grail has to be really good, otherwise, the CEO's door is for him to exit.
                      1
                      • see 150
                        5
                        • Next stop 275, if not held, it will visit 200 March low. I don't think the recent drop is entirely Grail acquisition related. Sellers just use that as excuses. Two days down 8% each on very heavy volume, finished days at low,..
                          2
                          • Heavy volume? Its been averaging 1 mil of less only today was its volume above 4 million
                            0
                        • Rather than bying Grail they should buy Guardant!
                          0
                          • On the way to make an acquisition, so it drops- I prefer Guardant even if expensive but they receive FDA approval both for covid test and cancer detectio liquid bloodtest
                            5
                            • too expensive
                              1
                              • Expensive for several reasons:  1) 70% of market share 2) consistently grow except during the pandemic 3) huge potential of the genetic field I'd love to see it drop to 200 again, but it will probably never see that price again unless they do a stock split.
                                0
                            • why it dropped so much so fast?
                              0
                              • Sundial growers next week 1,5 $
                                0
                                • 2019 july this stock drop 14%, same like today. looks like if wont hold 200 ema. usually sell off happen one or two days, not end in one day. high risk
                                  1
                                  • Huge buying opportunity
                                    2
                                    • not sure... i think 270-300 is possible
                                      1
                                    • really bad results. I think its gonna need a quarter to recover is upward trend.
                                      1
                                  • Buy now! Great moment!
                                    4
                                    • 3070430555638style picture
                                      1
                                      • JafarMalik9137132672
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.